Acute right-sided heart failure (RHF) is a complex clinical syndrome, with a wide range of clinical presentations, associated with increased mortality and morbidity, but with a scarcity of evidence-based literature. Temporary right ventricular assist device (t-RVAD) is a potential treatment option for selected patients with severe right ventricular dysfunction as a bridge-to-recovery or as a permanent solution.
(2022). 30-Day Survival After Temporary Right Ventricular Assist Devices: A Systematic Review. Cardiovascular Research Prove Journal, 6(1), -. doi: 10.21608/cvrepj.2022.351455
MLA
. "30-Day Survival After Temporary Right Ventricular Assist Devices: A Systematic Review", Cardiovascular Research Prove Journal, 6, 1, 2022, -. doi: 10.21608/cvrepj.2022.351455
HARVARD
(2022). '30-Day Survival After Temporary Right Ventricular Assist Devices: A Systematic Review', Cardiovascular Research Prove Journal, 6(1), pp. -. doi: 10.21608/cvrepj.2022.351455
VANCOUVER
30-Day Survival After Temporary Right Ventricular Assist Devices: A Systematic Review. Cardiovascular Research Prove Journal, 2022; 6(1): -. doi: 10.21608/cvrepj.2022.351455